Bill Text: IL HB3956 | 2013-2014 | 98th General Assembly | Amended

---

Bill Title: Amends the Illinois Savings and Loan Act of 1985. Makes a technical change in a Section concerning the short title.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Failed) 2014-12-03 - Session Sine Die [HB3956 Detail]

Download: Illinois-2013-HB3956-Amended.html

---

Rep. Sara Feigenholtz

Filed: 3/26/2014

09800HB3956ham001 LRB098 15516 ZMM 57504 a
AMENDMENT TO HOUSE BILL 3956
AMENDMENT NO. ______. Amend House Bill 3956 by replacing
everything after the enacting clause with the following:
"Section 5. The Pharmacy Practice Act is amended by adding
Section 25.25 as follows:
(225 ILCS 85/25.25 new)
Sec. 25.25. Opioid analgesic drugs.
(a) For the purposes of this Section:
"Interchange or substitution of an opioid analgesic drug"
means the substitution of any brand name or generic opioid
analgesic drug for a prescribed opioid analgesic drug
incorporating a tamper-resistance technology, whether or not
the substituted drug is rated as pharmaceutically and
therapeutically equivalent by the United States Food and Drug
Administration or the Board or whether the opioid analgesic
drug with tamper-resistance technology bears a labeling claim

09800HB3956ham001 - 2 - LRB098 15516 ZMM 57504 a
with respect to reduction of tampering, abuse, or abuse
potential.
"Opioid analgesic drug" means a drug in the opioid drug
class prescribed to treat moderate to severe pain or other
conditions, including opioid dependence, whether in immediate
release or extended release form and whether or not combined
with other drug substances to form a single tablet or other
dosage form.
"Opioid analgesic drug incorporating a tamper-resistance
technology" means an opioid analgesic drug listed as such by
the Board under subsection (b).
(b) The Board shall establish a list of the opioid
analgesic drugs for which it has received evidence from the
drug manufacturer or distributor that the drug incorporates a
tamper-resistance technology.
The list shall also include a determination by the Board as
to which of the opioid analgesic drugs incorporating
tamper-resistance technologies on the list provide
substantially similar tamper-resistance properties. Such a
determination by the Board shall be based solely on any studies
submitted to the United States Food and Drug Administration
with the drug manufacturer's application for approval.
(c) The Board shall not exclude an opioid analgesic drug
from the list established under subsection (b) on the basis
that the drug does not bear a labeling claim with respect to
reduction of tampering, abuse, or abuse potential at the time

09800HB3956ham001 - 3 - LRB098 15516 ZMM 57504 a
the drug is being considered for placement on the list or any
time after the drug's placement on the list.
(d) A pharmacist shall not interchange or substitute a
brand name or generic opioid analgesic drug otherwise eligible
for interchange or substitution under this Section without
doing one of the following:
(1) verifying that the Board has determined under
subsection (b) that the opioid analgesic drug provides
tamper-resistance properties substantially similar to the
prescribed opioid analgesic drug incorporating a
tamper-resistance technology; or
(2) obtaining written, signed consent from the
prescriber for the interchange or substitution.
Section 99. Effective date. This Act takes effect January
1, 2015.".